A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia
Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinical...
Gespeichert in:
| Veröffentlicht in: | Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2015-06, Vol.15 (6), p.377-383 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 383 |
|---|---|
| container_issue | 6 |
| container_start_page | 377 |
| container_title | Clinical lymphoma, myeloma and leukemia |
| container_volume | 15 |
| creator | Mannis, Gabriel N Andreadis, Charalambos Logan, Aaron C Damon, Lloyd E Benet, Leslie Z Ai, Weiyun Z Gaensler, Karin M.L Kaplan, Lawrence D Koplowicz, Yelena B Linker, Charles A Olin, Rebecca L Sayre, Peter H Smith, Catherine C Sudhindra, Akshay Venstrom, Jeffrey M Wolf, Jeffrey L Martin, Thomas G |
| description | Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinically acceptable dose. This busulfan AUC target might be associated with improved relapse-free survival. |
| doi_str_mv | 10.1016/j.clml.2015.02.016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1686418939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S2152265015000452</els_id><sourcerecordid>1686418939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-872bf59011fde90d2087d562928d219a74aad48d4eab2e7e6deb228a8bae43713</originalsourceid><addsrcrecordid>eNp9ks-O0zAQxiMEYpeFF-CAfORAiu3mr4SQSilQqQikFnG0JvFk665jB9up1Ffj6XCUZQ8cONkefd9PM_4mSV4yumCUFW9Pi1b3esEpyxeUL2LpUXLNWc5TXhT144d7Tq-SZ96fKC0pZfXT5IrnZVmwenmd_F6R70fwSLZkH0Z5IbYjB3C3GFC-IR-tx3TjW9AQ32RrgoMzGjt68mH0o-7AEGXI2vaNMhCUNeSnCkeyCXawXkkk4MnXC2oLTUSoM5LDER0MF9JZR1ZjsNreTrh9wJ6sUWtycGD8oMGEGRj5q3YMOHOUJDsc77BX8Dx50oH2-OL-vEl-fNoc1l_S3bfP2_Vql7ZZxUJalbzp8poy1kmsqeS0KmVe8JpXkrMaygxAZpXMEBqOJRYSG84rqBrAbFmy5U3yeuYOzv4a0QfRK9_GVsFgbF2woioyVtXLOkr5LG2d9d5hJwanenAXwaiYMhMnMWUmpswE5SKWounVPX9sepQPlr8hRcG7WYBxyrNCJ3yr0LQolcM2CGnV__nv_7G3WhkVQ73DC_qTHZ2J_yeY8NEg9tPWTEvDckpplvPlH5nzv_8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1686418939</pqid></control><display><type>article</type><title>A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Mannis, Gabriel N ; Andreadis, Charalambos ; Logan, Aaron C ; Damon, Lloyd E ; Benet, Leslie Z ; Ai, Weiyun Z ; Gaensler, Karin M.L ; Kaplan, Lawrence D ; Koplowicz, Yelena B ; Linker, Charles A ; Olin, Rebecca L ; Sayre, Peter H ; Smith, Catherine C ; Sudhindra, Akshay ; Venstrom, Jeffrey M ; Wolf, Jeffrey L ; Martin, Thomas G</creator><creatorcontrib>Mannis, Gabriel N ; Andreadis, Charalambos ; Logan, Aaron C ; Damon, Lloyd E ; Benet, Leslie Z ; Ai, Weiyun Z ; Gaensler, Karin M.L ; Kaplan, Lawrence D ; Koplowicz, Yelena B ; Linker, Charles A ; Olin, Rebecca L ; Sayre, Peter H ; Smith, Catherine C ; Sudhindra, Akshay ; Venstrom, Jeffrey M ; Wolf, Jeffrey L ; Martin, Thomas G</creatorcontrib><description>Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinically acceptable dose. This busulfan AUC target might be associated with improved relapse-free survival.</description><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2015.02.016</identifier><identifier>PMID: 25776193</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute Myelogenous Leukemia ; Administration, Intravesical ; Adult ; Area Under Curve ; Autologous transplant ; Busulfan - administration & dosage ; Busulfan - adverse effects ; Busulfan - pharmacokinetics ; Disease-Free Survival ; Etoposide - administration & dosage ; Hematology, Oncology and Palliative Medicine ; Hematopoietic Stem Cell Transplantation ; High-dose chemotherapy ; Humans ; Leukemia, Myeloid, Acute - therapy ; Maximum Tolerated Dose ; Middle Aged ; Mucositis - chemically induced ; Myeloablative Agonists - administration & dosage ; Myeloablative Agonists - adverse effects ; Myeloablative Agonists - pharmacokinetics ; Pharmacokinetics ; Phase I Clinical Trial ; Recurrence ; Transplantation Conditioning - methods ; Transplantation, Autologous ; Young Adult</subject><ispartof>Clinical lymphoma, myeloma and leukemia, 2015-06, Vol.15 (6), p.377-383</ispartof><rights>2015</rights><rights>Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-872bf59011fde90d2087d562928d219a74aad48d4eab2e7e6deb228a8bae43713</citedby><cites>FETCH-LOGICAL-c481t-872bf59011fde90d2087d562928d219a74aad48d4eab2e7e6deb228a8bae43713</cites><orcidid>0000-0003-4681-6227</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2152265015000452$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25776193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mannis, Gabriel N</creatorcontrib><creatorcontrib>Andreadis, Charalambos</creatorcontrib><creatorcontrib>Logan, Aaron C</creatorcontrib><creatorcontrib>Damon, Lloyd E</creatorcontrib><creatorcontrib>Benet, Leslie Z</creatorcontrib><creatorcontrib>Ai, Weiyun Z</creatorcontrib><creatorcontrib>Gaensler, Karin M.L</creatorcontrib><creatorcontrib>Kaplan, Lawrence D</creatorcontrib><creatorcontrib>Koplowicz, Yelena B</creatorcontrib><creatorcontrib>Linker, Charles A</creatorcontrib><creatorcontrib>Olin, Rebecca L</creatorcontrib><creatorcontrib>Sayre, Peter H</creatorcontrib><creatorcontrib>Smith, Catherine C</creatorcontrib><creatorcontrib>Sudhindra, Akshay</creatorcontrib><creatorcontrib>Venstrom, Jeffrey M</creatorcontrib><creatorcontrib>Wolf, Jeffrey L</creatorcontrib><creatorcontrib>Martin, Thomas G</creatorcontrib><title>A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia</title><title>Clinical lymphoma, myeloma and leukemia</title><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><description>Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinically acceptable dose. This busulfan AUC target might be associated with improved relapse-free survival.</description><subject>Acute Myelogenous Leukemia</subject><subject>Administration, Intravesical</subject><subject>Adult</subject><subject>Area Under Curve</subject><subject>Autologous transplant</subject><subject>Busulfan - administration & dosage</subject><subject>Busulfan - adverse effects</subject><subject>Busulfan - pharmacokinetics</subject><subject>Disease-Free Survival</subject><subject>Etoposide - administration & dosage</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>High-dose chemotherapy</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Maximum Tolerated Dose</subject><subject>Middle Aged</subject><subject>Mucositis - chemically induced</subject><subject>Myeloablative Agonists - administration & dosage</subject><subject>Myeloablative Agonists - adverse effects</subject><subject>Myeloablative Agonists - pharmacokinetics</subject><subject>Pharmacokinetics</subject><subject>Phase I Clinical Trial</subject><subject>Recurrence</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplantation, Autologous</subject><subject>Young Adult</subject><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks-O0zAQxiMEYpeFF-CAfORAiu3mr4SQSilQqQikFnG0JvFk665jB9up1Ffj6XCUZQ8cONkefd9PM_4mSV4yumCUFW9Pi1b3esEpyxeUL2LpUXLNWc5TXhT144d7Tq-SZ96fKC0pZfXT5IrnZVmwenmd_F6R70fwSLZkH0Z5IbYjB3C3GFC-IR-tx3TjW9AQ32RrgoMzGjt68mH0o-7AEGXI2vaNMhCUNeSnCkeyCXawXkkk4MnXC2oLTUSoM5LDER0MF9JZR1ZjsNreTrh9wJ6sUWtycGD8oMGEGRj5q3YMOHOUJDsc77BX8Dx50oH2-OL-vEl-fNoc1l_S3bfP2_Vql7ZZxUJalbzp8poy1kmsqeS0KmVe8JpXkrMaygxAZpXMEBqOJRYSG84rqBrAbFmy5U3yeuYOzv4a0QfRK9_GVsFgbF2woioyVtXLOkr5LG2d9d5hJwanenAXwaiYMhMnMWUmpswE5SKWounVPX9sepQPlr8hRcG7WYBxyrNCJ3yr0LQolcM2CGnV__nv_7G3WhkVQ73DC_qTHZ2J_yeY8NEg9tPWTEvDckpplvPlH5nzv_8</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Mannis, Gabriel N</creator><creator>Andreadis, Charalambos</creator><creator>Logan, Aaron C</creator><creator>Damon, Lloyd E</creator><creator>Benet, Leslie Z</creator><creator>Ai, Weiyun Z</creator><creator>Gaensler, Karin M.L</creator><creator>Kaplan, Lawrence D</creator><creator>Koplowicz, Yelena B</creator><creator>Linker, Charles A</creator><creator>Olin, Rebecca L</creator><creator>Sayre, Peter H</creator><creator>Smith, Catherine C</creator><creator>Sudhindra, Akshay</creator><creator>Venstrom, Jeffrey M</creator><creator>Wolf, Jeffrey L</creator><creator>Martin, Thomas G</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4681-6227</orcidid></search><sort><creationdate>20150601</creationdate><title>A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia</title><author>Mannis, Gabriel N ; Andreadis, Charalambos ; Logan, Aaron C ; Damon, Lloyd E ; Benet, Leslie Z ; Ai, Weiyun Z ; Gaensler, Karin M.L ; Kaplan, Lawrence D ; Koplowicz, Yelena B ; Linker, Charles A ; Olin, Rebecca L ; Sayre, Peter H ; Smith, Catherine C ; Sudhindra, Akshay ; Venstrom, Jeffrey M ; Wolf, Jeffrey L ; Martin, Thomas G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-872bf59011fde90d2087d562928d219a74aad48d4eab2e7e6deb228a8bae43713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acute Myelogenous Leukemia</topic><topic>Administration, Intravesical</topic><topic>Adult</topic><topic>Area Under Curve</topic><topic>Autologous transplant</topic><topic>Busulfan - administration & dosage</topic><topic>Busulfan - adverse effects</topic><topic>Busulfan - pharmacokinetics</topic><topic>Disease-Free Survival</topic><topic>Etoposide - administration & dosage</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>High-dose chemotherapy</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Maximum Tolerated Dose</topic><topic>Middle Aged</topic><topic>Mucositis - chemically induced</topic><topic>Myeloablative Agonists - administration & dosage</topic><topic>Myeloablative Agonists - adverse effects</topic><topic>Myeloablative Agonists - pharmacokinetics</topic><topic>Pharmacokinetics</topic><topic>Phase I Clinical Trial</topic><topic>Recurrence</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplantation, Autologous</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mannis, Gabriel N</creatorcontrib><creatorcontrib>Andreadis, Charalambos</creatorcontrib><creatorcontrib>Logan, Aaron C</creatorcontrib><creatorcontrib>Damon, Lloyd E</creatorcontrib><creatorcontrib>Benet, Leslie Z</creatorcontrib><creatorcontrib>Ai, Weiyun Z</creatorcontrib><creatorcontrib>Gaensler, Karin M.L</creatorcontrib><creatorcontrib>Kaplan, Lawrence D</creatorcontrib><creatorcontrib>Koplowicz, Yelena B</creatorcontrib><creatorcontrib>Linker, Charles A</creatorcontrib><creatorcontrib>Olin, Rebecca L</creatorcontrib><creatorcontrib>Sayre, Peter H</creatorcontrib><creatorcontrib>Smith, Catherine C</creatorcontrib><creatorcontrib>Sudhindra, Akshay</creatorcontrib><creatorcontrib>Venstrom, Jeffrey M</creatorcontrib><creatorcontrib>Wolf, Jeffrey L</creatorcontrib><creatorcontrib>Martin, Thomas G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mannis, Gabriel N</au><au>Andreadis, Charalambos</au><au>Logan, Aaron C</au><au>Damon, Lloyd E</au><au>Benet, Leslie Z</au><au>Ai, Weiyun Z</au><au>Gaensler, Karin M.L</au><au>Kaplan, Lawrence D</au><au>Koplowicz, Yelena B</au><au>Linker, Charles A</au><au>Olin, Rebecca L</au><au>Sayre, Peter H</au><au>Smith, Catherine C</au><au>Sudhindra, Akshay</au><au>Venstrom, Jeffrey M</au><au>Wolf, Jeffrey L</au><au>Martin, Thomas G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>15</volume><issue>6</issue><spage>377</spage><epage>383</epage><pages>377-383</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><abstract>Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinically acceptable dose. This busulfan AUC target might be associated with improved relapse-free survival.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25776193</pmid><doi>10.1016/j.clml.2015.02.016</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4681-6227</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2152-2650 |
| ispartof | Clinical lymphoma, myeloma and leukemia, 2015-06, Vol.15 (6), p.377-383 |
| issn | 2152-2650 2152-2669 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1686418939 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acute Myelogenous Leukemia Administration, Intravesical Adult Area Under Curve Autologous transplant Busulfan - administration & dosage Busulfan - adverse effects Busulfan - pharmacokinetics Disease-Free Survival Etoposide - administration & dosage Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation High-dose chemotherapy Humans Leukemia, Myeloid, Acute - therapy Maximum Tolerated Dose Middle Aged Mucositis - chemically induced Myeloablative Agonists - administration & dosage Myeloablative Agonists - adverse effects Myeloablative Agonists - pharmacokinetics Pharmacokinetics Phase I Clinical Trial Recurrence Transplantation Conditioning - methods Transplantation, Autologous Young Adult |
| title | A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T23%3A10%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Phase%20I%20Study%20of%20Targeted,%20Dose-Escalated%20Intravenous%20Busulfan%20in%20Combination%20With%20Etoposide%20as%20Myeloablative%20Therapy%20for%20Autologous%20Stem%20Cell%20Transplantation%20in%20Acute%20Myeloid%20Leukemia&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Mannis,%20Gabriel%20N&rft.date=2015-06-01&rft.volume=15&rft.issue=6&rft.spage=377&rft.epage=383&rft.pages=377-383&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2015.02.016&rft_dat=%3Cproquest_cross%3E1686418939%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1686418939&rft_id=info:pmid/25776193&rft_els_id=1_s2_0_S2152265015000452&rfr_iscdi=true |